News

1st Patient Dosed in Phase 1/2 Trial of Antibody Therapy ISB 1442

The first patient has been dosed in Ichnos Sciences’ Phase 1/2 clinical trial investigating ISB 1442, an experimental bi-specific antibody treatment for people with relapsed or refractory multiple myeloma. ISB 1442 targets two proteins on cancer cells, CD47 and CD38, and also binds to immune cells. These simultaneous…

MCARH109, CAR T-cell Therapy for Advanced MM, Shows Potential

A new investigational CAR T-cell therapy, called MCARH109, demonstrated an ability to shrink or eliminate the amount of cancer in patients with relapsed or refractory multiple myeloma, according to results from a dose-escalation Phase 1 trial. Safety findings showed the treatment at its highest dose was not safe for…

M-Power Project for African Americans Now Includes New York

The International Myeloma Foundation’s (IMF) M-Power project, which seeks to improve disease outcomes for African Americans with multiple myeloma, has formed a partnership with yet another U.S. city, this time New York. Myeloma is the most common blood cancer among Black Americans, who have an above-average risk of the…

OCEAN Trial Fails to Support Pepaxto for RRMM, FDA Panel Finds

An advisory panel to the U.S. Food and Drug Administration (FDA) has overwhelmingly decided that the Phase 3 OCEAN clinical trial did not provide sufficient evidence to support Pepaxto (melphalan flufenamide) as a treatment for relapsed or refractory multiple myeloma (RRMM). Notably, while the FDA will consider the committee’s…

IMF Focuses on Education for Blood Cancer Awareness Month

For this Blood Cancer Awareness Month, observed each September, the International Myeloma Foundation (IMF) is focusing on educating people about multiple myeloma, the second most common type of blood cancer. The month is set aside to heighten awareness about all blood cancers, which are diagnosed every three minutes…

Pepaxti Approved to Treat Resistant Multiple Myeloma in Europe

The European Commission has approved Pepaxti (melphalan flufenamide, also called melflufen), a medicine by Oncopeptides to be used in combination with dexamethasone, making it available to adults with hard-to-treat multiple myeloma in Europe. The approval came after the Committee for Medicinal Products for Human Use, an arm of…

Abecma May Be Effective Early Therapy for Hard-to-treat Myeloma

Note: This story was updated Sept. 26, 2022, to correct the fact that Abecma is approved for patients in Europe and Japan who have undergone at least three prior therapies, not four as originally stated.  The CAR T-cell therapy Abecma (idecabtagene vicleucel) significantly extended survival without signs of disease worsening…